|
|
壳聚糖–海藻酸钠–丹参酮IIA微球的制备及其工艺优化
|
Abstract:
目的：优化壳聚糖–海藻酸钠(CS-SA)包裹丹参酮IIA (TIIA)的工艺条件，得到最佳工艺。方法：研究海藻酸钠含量、壳聚糖含量、Ca2+含量、Span-80等工艺条件对微球粒径分布的影响，在此基础上，研究SA、CS、Ca2+含量对载药量的影响，以工艺参数进行优化。结果：最佳工艺条件：SA含量为1.5%、Ca2+含量30%、CS含量0.4%，在该最佳工艺条件下，最大载药量达到13.2%。结论：为CS-SA包裹TIIA工业化生产应用提供了方向。
Objective: The research aimed to optimize the process conditions of tanshinone IIA (TIIA) encapsulated by chitosan-sodium alginate (CS-SA) and obtain the best process. Method: The effects of sodium alginate content, chitosan content, Ca2+ content, Span-80 and other process conditions on the particle size distribution of microspheres were studied. On this basis, the effects of SA, CS and Ca2+ content on drug loading were studied. The process parameters were optimized. Result: The optimal process conditions: SA content was 1.5%, Ca2+ content was 30%, CS content was 0.4%. Under the optimal process conditions, the maximum drug loading amount reached 13.2%. Conclusion: It provides a direction for the industrial production and application of CS-SA wrapped TIIA.
| [1] | Berger, J., Reist, M., Mayer, J.M., et al. (2004) Structure and Interactions in Covalently and Ionically Crosslinked Chitosan Hydrogels for Biomedical Applications. European Journal of Pharmaceutics and Biopharmaceutics, 57, 19-34. https://doi.org/10.1016/S0939-6411(03)00161-9 |
| [2] | Caetano, L.A., Almeida, A.J. and Gon？alves, L. (2016) Effect of Experimental Parameters on Alginate/Chitosan Microparticle for BCG Encapsulation. Marine Drugs, 14, 85-90. https://doi.org/10.3390/md14050090 |
| [3] | Dragan, E.S. (2014) Design and Applications of Interpenetrating Polymer Network Hydrogels. Chemical Engineering Journal, 243, 572-590. https://doi.org/10.1016/j.cej.2014.01.065 |
| [4] | Han, J.Y., Fan, J.Y., Horie, Y., et al. (2008) Ameliorating Effects of Compounds Derived from Salvia miltiorrhiza Root Extract on Microcirculatory Disturbance and Target Organ Injury by Ischemia and Reperfusion. Pharmacology & Therapeutics, 117, 280-295. https://doi.org/10.1016/j.pharmthera.2007.09.008 |
| [5] | Song, T., Yao, Y., Wang, T., et al. (2017) Tanshinone IIA Ameliorates Apoptosis of Myocardiocytes by Up-Regulation of miR-133 and Suppression of Caspase-9. European Journal of Pharmacology, 815, 343-350.
https://doi.org/10.1016/j.ejphar.2017.08.041 |
| [6] | Fu, J.J., Huang, H.Q., Liu, J.J., et al. (2007) Tanshinone IIA Protects Cardiac Myocytes against Oxidative Stress-Triggered Damage and Apoptosis. European Journal of Pharmacology, 568, 213-221.
https://doi.org/10.1016/j.ejphar.2007.04.031 |
| [7] | Zhou, W. and Wang, Y.H. (2014) A Network-Based Analysis of the Types of Coronary Artery Disease from Traditional Chinese Medicine Perspective: Potential for Therapeutics and Drug Discovery. Journal of Ethnopharmacology, 151, 66-77. https://doi.org/10.1016/j.jep.2013.11.007 |
| [8] | Lin, C.Y., Wang, L., Wang, L.L., et al. (2013) Tanshinone IIA Inhibits Breast Cancer Stem Cells Growth in Vitro and in Vivo through Attenuation of IL-6/STAT3/NF-κB Signaling Pathways. Journal of Cellular Biochemistry, 114, 2061-2070. https://doi.org/10.1002/jcb.24553 |
| [9] | Zhang, W.L., He, H.L., Liu, J.P., et al. (2013) Pharmacokinetics and Atherosclerotic Lesions Targeting Effects of Tanshinone IIA Discoidal and Spherical Biomimetic High Density Lipoproteins. Biomaterials, 34, 306-319.
https://doi.org/10.1016/j.biomaterials.2012.09.058 |
